New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:12 EDTKERXKeryx Biopharmaceuticals announces filing of NDA for Ferric Citrate in Japan
Keryx Biopharmaceuticals announced that its Japanese partner, Japan Tobacco, has filed its New Drug Application with the Japanese Ministry of Health, Labour and Welfare for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. The NDA filing is supported by efficacy and safety data from several successfully completed Phase 3 studies in CKD patients with hyperphosphatemia in Japan. Under the license agreement with JT and its subsidiary Torii Pharmaceutical Co. within 30 days, Keryx will receive a non-refundable payment of $7M for the achievement of the NDA filing milestone.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:48 EDTKERXKeryx management to meet with JMP SEcurities
Subscribe for More Information
March 23, 2015
13:43 EDTKERXKeryx mentioned cautiously in a Seeking Alpha Pro article
Subscribe for More Information
March 20, 2015
07:55 EDTKERXKeryx survey results positive, says Oppenheimer
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use